Highly potent and selective αVβ3-receptor antagonists: Solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 2, 2003, Pages 165-169

  Zechel, Christian ^a,c   Backfisch, Gisela ^b   Delzer, Jürgen ^b   Geneste, Hervé ^b   Graef, Claudia ^a   Hornberger, Wilfried ^b   Kling, Andreas ^b   Lange, Udo E W ^a   Lauterbach, Arnulf ^a   Seitz, Werner ^a   Subkowski, Thomas ^a  

^a BASF SE   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIAMINOPROPIONIC ACID; 3,4 DIAMINOBUTYRIC ACID; 4 AMINO 1H PYRIMIDIN 2 ONE; ALPHA 5 BETA 3 RECEPTOR; BUTYRIC ACID DERIVATIVE; INTEGRIN; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GUANIDINE DERIVATIVE; LIGAND; PYRIMIDINONE DERIVATIVE; VITRONECTIN RECEPTOR;

ARTICLE; ASSAY; DRUG ANTAGONISM; DRUG SYNTHESIS; IC 50; STRUCTURE ACTIVITY RELATION; COMBINATORIAL CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; MOLECULAR MIMICRY; SYNTHESIS;

COMBINATORIAL CHEMISTRY TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUANIDINES; INDICATORS AND REAGENTS; INTEGRIN ALPHAVBETA3; LIGANDS; MOLECULAR MIMICRY; PYRIMIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17944391700     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00931-9     Document Type: Article

References (45)

1. Eble J.A., Kühn K. Integrin-ligand Interaction. 1997;Springer, Heidelberg.
2. (a) Cox D. Drug News Perspect. 8:1995;197.
3. (b) Hillis G.S., MacLeod A.M. Clin. Sci. 91:1996;639.
4. Coller B.S. J. Clin. Invest. 99:1997;1467.
5. Brooks P.C., Clark R.A.F., Cheresh D.A. Science. 264:1994;569.
6. Bishop G.G., McPherson J.A., Sanders J.M., Hesselbacher S.E., Feldman M.J., McNamara C.A., Gimpel L.W., Powers E.R., Mousa S.A., Sarembock I.J. Circulation. 103:2001;1906.
7. Mousa S.A. Exp. Opin. Ther. Pat. 9:1999;1237.
8. Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., Cheresh D.A. J. Clin. Invest. 103:1999;47.
9. Hammes H.P., Brownlee M., Jonczyk A., Sutter A., Preissner K.T. Nat. Med. 2:1996;529.
10. Marshall J.F., Hart I.R. Sem. Cancer Biol. 7:1996;129.
11. Chorev M., Dresner-Pollak R., Eshel Y., Rosenblatt M. Biopolymers (Pept. Sci.). 37:1995;367.
12. Noiri E., Gailit J., Sheth D., Magazine H., Gurrath M., Müller G., Kessler H., Goligorsky M.S. Kidney Int. 46:1994;1050.
13. (a) Brooks P.C. Drug News Perspect. 10:1997;456.
14. (b) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Discov. Today. 5:2000;397.
15. Ruoslahti E. Annu. Rev. Cell Dev. Biol. 12:1996;697.
16. Haubner R., Finsinger D., Kessler H. Angew. Chem., Int. Ed. Engl. 36:1997;1374.
17. Xiong J.-P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnout M.A. Science. 296:2002;151.
18. (a) Hoekstra W.J., Poulter B.L. Curr. Med. Chem. 5:1998;195.
19. (b) Rockwell A.L., Rafalski M., Pitts W.J., Batt D.G., Petraitis J.J., DeGrado W.F., Mousa S., Jadhav P.K. Bioorg. Med. Chem. Lett. 9:1999;937.
20. (c) Duggan M.E., Hutchinson J.H. Exp. Opin. Ther. Pat. 10:2000;1367.
21. (d) Gopalsamy A., Yang H., Ellingboe J.W., Kees K.L., Yoon J., Murrills R. Bioorg. Med. Chem. Lett. 10:2000;1715.
22. (e) Sulyok G.A., Gibson C., Goodman S.L., Hölzemann G., Wiesner M., Kessler H. J. Med. Chem. 44:2001;1938.
23. Scarborough R.M. Curr. Med. Chem. 6:1999;971.
24. (a) Kling A., Backfisch G., Delzer J., Geneste H., Graef C., Holzenkamp U., Hornberger W., Lange U.E.W., Lauterbach A., Mack H., Seitz W., Subkowski T. Bioorg. Med. Chem. Lett. 12:2002;441.
25. (b) Lange U.E.W., Backfisch G., Delzer J., Geneste H., Graef C., Hornberger W., Kling A., Lauterbach A., Subkowski T., Zechel C. Bioorg. Med. Chem. Lett. 12:2002;1379.
26. (c) Kling, A.; Backfisch, G.; Delzer, J.; Geneste, H.; Graef, C.; Hornberger, W.; Lange, U. E. W.; Lauterbach, A.; Seitz, W.; Subkowski, T. Bioorg. Med. Chem. In press.
27. (a) Recent examples for the use of heterocycles as scaffolds for integrin antagonists: Peyman A., Gourvest J.-F., Gadek T.R., Knolle J. Angew. Chem. 112:2000;2996. Peyman A., Gourvest J.-F., Gadek T.R., Knolle J. Angew. Chem., Int. Ed. Engl. 39:2000;2874.
28. (a) Recent examples for the use of heterocycles as scaffolds for integrin antagonists: Peyman A., Gourvest J.-F., Gadek T.R., Knolle J. Angew. Chem. 112:2000;2996. Peyman A., Gourvest J.-F., Gadek T.R., Knolle J. Angew. Chem., Int. Ed. Engl. 39:2000;2874.
29. (b) Pitts W.J., Wityak J., Smallheer J.M., Tobin A.E., Jetter J.W., Buynitsky J.S., Harlow P.P., Solomon K.A., Corjay M.H., Mousa S.A., Wexler R.R., Jadhav P.K. J. Med. Chem. 43:2000;27.
30. (c) Batt D.G., Petraitis J.J., Houghton G.C., Modi D.P., Cain G.A., Corjay M.H., Mousa S.A., Bouchard P.J., Forsythe M.S., Harlow P.P., Barbera F.A., Spitz S.M., Wexler R.R., Jadhav P.K. J. Med. Chem. 43:2000;41.
31. (d) Peyman A., Scheunemann K.-H., Will D.W., Knolle J., Wehner V., Breipohl G., Stilz H.-U., Carniato D., Ruxer J.-M., Gourvest J.-F., Auberval M., Doucet B., Baron R., Gaillard M., Gadek T.R., Bodary S. Bioorg. Med. Chem. Lett. 11:2001;2011.
32. (e) Meissner R.S., Perkins J.J., Duong L.T., Hartman G.D., Hoffman W.F., Huff J.R., Ihle N.C., Leu C.-T., Nagy R.M., Naylor-Olsen A., Rodan G.A., Rodan S.B., Whitman D.B., Wesolowski G.A., Duggan M.E. Bioorg. Med. Chem. Lett. 12:2002;25.
33. (f) Coleman P.J., Brashear K.M., Hunt C.A., Hoffman W.F., Hutchinson J.H., Breslin M.J., McVean C.A., Askew B.C., Hartman G.D., Rodan S.B., Rodan G.A., Leu C.-T., Prueksaritanont T., Fernandez-Metzler C., Ma B., Libby L.A., Merkle K.M., Stump G.L., Wallace A.A., Lynch J.J., Lynch R., Duggan M.E. Bioorg. Med. Chem. Lett. 12:2002;31.
34. Z-Dap(Fmoc)-OH and Z-Dab(Fmoc)-OH were obtained from Neosystem and Bissendorf Pharmaceuticals, respectively.
35. Barlos K., Gatos D., Kapolos S., Papaphotiu G., Schaefer W., Wenquing Y. Tetrahedron Lett. 30:1989;3947.
36. Lamon R.W. J. Heterocycl. Chem. 5:1968;837.
37. (a) Nikiforov T.T., Connolly B.A. Tetrahedron Lett. 32:1991;2505.
38. (b) Nikiforov T.T., Connolly B.A. Tetrahedron Lett. 32:1991;3851.
39. The ELISA assay as well as the preparation of the amine building blocks mentioned is described in: WO 0066618, 2001; Chem. Abstr. 2001, 133, 350516.
40. (a) Lin K., Ateeq H.S., Hsiung S.H., Chong L.T., Zimmerman C.N., Castro A., Lee W.C., Hammond C.E., Kalkunte S., Chen L.L., Pepinsky R.B., Leone D.R., Sprague A.G., Abraham W.M., Gill A., Lobb R.R., Adams S.P. J. Med. Chem. 42:1999;920.
41. (b) Duplantier A.J., Beckius G.E., Chambers R.J., Chupak L.S., Jenkinson T.H., Klein A.S., Kraus K.G., Kudlacz E.M., McKechney M.W., Pettersson M.P., Whitney C.A., Milici A.J. Bioorg. Med. Chem. Lett. 11:2001;2593
42. (c) Urbahns K., Härter M., Albers M., Schmidt D., Stelte-Ludwig B., Brüggemeier U., Vaupel A., Gerdes C. Bioorg. Med. Chem. Lett. 12:2002;205.
43. (a) Hilgers A.R., Conradi R.A., Burton P.S. Pharm. Res. 7:1990;902.
44. (b) Artursson P. Crit. Rev. Ther. Drug Carrier System. 8:1991;105.
45. app values >2e-7 cm/s are considered as medium, >2e-6 cm/s as high transport rate.